Abstract
Inhibition of mTOR increases the antitumor activity of T-DM1, supporting that the combination of mTOR inhibitors and antibody-drug conjugates warrants clinical evaluation in patients with HER2-positive breast cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have